Phase II study of carfilzomib (CFZ) in combination with current agents for relapsed and refractory multiple myeloma (RRMM).
J. Szymonifka
No relevant relationships to disclose
S. Z. Usmani
Consultant or Advisory Role - Onyx (U)
Research Funding - Onyx
R. Sexton
No relevant relationships to disclose
S. Panozzo
No relevant relationships to disclose
B. P. Nair
No relevant relationships to disclose
S. Waheed
No relevant relationships to disclose
Y. Alsayed
No relevant relationships to disclose
J. Crowley
No relevant relationships to disclose
B. Barlogie
No relevant relationships to disclose